Organization (Hospital)
Douglas Mental Health University Institute
ClinicalTrials.gov lists Douglas Mental Health University Institute as lead sponsor of 39 trials. It has 12 active development programs and 5 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 2 registered with a 2026 start date. The dashed outline is the pace from the 2 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 3.6 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Douglas Mental Health University Institute: 39 lead-sponsored trials and 1 legal-entity registration.
Disease areas (27)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Psychotic Disorders | 12 |
| Schizophrenia | 8 |
| Bipolar Disorder | 6 |
| Cognitive Dysfunction | 5 |
| Major Depressive Disorder | 5 |
Showing 5 of 27 disease areas.
Trials by start year as sponsor or collaborator (17)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 3 |
| 2024 | 5 |
| 2023 | 5 |
| 2022 | 3 |
| 2021 | 4 |
| 2018 | 1 |
| 2017 | 1 |
| 2016 | 2 |
| 2015 | 1 |
Showing 10 of 17 years.
Prediction, not a registry value: median of 36 months from start to primary completion across 5 trials still running at the 2026-10-09 snapshot; registered median of 21 months across 23 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (12)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Brexpiprazole | Depressive Disorder, Treatment-Resistant | Phase 3 | 1 |
| Brexpiprazole | Bipolar Disorder | Phase 3 | 1 |
| Daridorexant 50 mg | Alzheimer Disease | Phase 2 | 1 |
| Daridorexant 50 mg | Pick Disease of the Brain | Phase 2 | 1 |
| Daridorexant 50 mg | Dementia | Phase 2 | 1 |
Showing 5 of 12 active programs.
Approved assets (5)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Brexpiprazole | 1 |
| PROPRANOLOL | 3 |
| Naproxen | 1 |
| Probucol | 1 |
| MELATONIN | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 27% hit target (n=11) | 20% on time (n=10) |
Journals published in (108)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Bipolar disorders | 12 |
| Journal of affective disorders | 12 |
| Development and psychopathology | 5 |
| The American journal of psychiatry | 5 |
| Acta paediatrica (Oslo, Norway : 1992) | 4 |
Showing 5 of 108 journals.
Organization relationships (7)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Montreal Neurological Institute and Hospital | Co sponsors trial with | 1 |
| London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Co sponsors trial with | 1 |
| Blema & Arnold Steinberg Family Foundation | Co sponsors trial with | 1 |
| WOCO Foundation | Co sponsors trial with | 1 |
| Norlien Foundation | Co sponsors trial with | 1 |
Showing 5 of 7 relationships.
Latest dated events (41)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-08 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-02-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-10-14 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-06-15 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-05-19 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 41 events.
Biomarker capability evidence (44)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| APOE | Trial sponsor | Named in trial inclusion criteria |
| HPSE | Trial collaborator | Named in trial inclusion criteria |
| KIAA1217 | Trial sponsor | Named in trial inclusion criteria |
| PRL | Trial sponsor | Named in trial inclusion criteria |
| SPIN1 | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 44 evidence rows.
Biomarkers this organization publishes on (102)
Shown in this order: most publications first.
Showing 5 of 102 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.